Remicade Patent Fight: Janssen Loses Big, But Pfizer Not Out Of Woods

Pfizer would still be at risk for damages from biosimilar launch if Janssen's manufacturing process patent is upheld even as US Federal Circuit affirms that patent covering Remicade's active ingredient is invalid.